Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer

Standard treatment for irresectable stage III non-small cell lung cancer (NSCLC) is concurrent/sequential chemoradiation. Despite this intensive therapy, prognosis remains poor with 5-year survival of 13-36% [1]. Locoregional progression and distant metastases remain a major issue [2]. Therefore, further intensification of treatment is required.

Source: Lung Cancer - October 15, 2018 Category: Cancer & Oncology Authors: Tineke W.H Meijer, Wenny J.M. Peeters, Ludwig J. Dubois, Marike W. van Gisbergen, Rianne Biemans, Jan-Hendrik Venhuizen, Paul N. Span, Johan Bussink Source Type: research